Skoči na glavni sadržaj

Sažetak sa skupa

https://doi.org/10.15836/ccar2024.478

Stentless percutaneous coronary interventions: niche or standard?

Irzal Hadžibegović orcid id orcid.org/0000-0002-3768-9134 ; Dubrava University Hospital, Zagreb, Croatia
Ivana Jurin orcid id orcid.org/0000-0002-2637-9691 ; Dubrava University Hospital, Zagreb, Croatia
Tomislav Šipić orcid id orcid.org/0000-0001-8652-4523 ; Dubrava University Hospital, Zagreb, Croatia
Marin Pavlov orcid id orcid.org/0000-0003-3962-2774 ; Dubrava University Hospital, Zagreb, Croatia
Aleksandar Blivajs orcid id orcid.org/0000-0003-3404-3837 ; Dubrava University Hospital, Zagreb, Croatia
Nikola Pavlović orcid id orcid.org/0000-0001-9187-7681 ; Dubrava University Hospital, Zagreb, Croatia
Ante Lisičić orcid id orcid.org/0000-0002-4365-9652 ; Dubrava University Hospital, Zagreb, Croatia
Mario Udovičić orcid id orcid.org/0000-0001-9912-2179 ; Dubrava University Hospital, Zagreb, Croatia
Tomislav Čikara orcid id orcid.org/0000-0001-8012-4481 ; Dubrava University Hospital, Zagreb, Croatia
Miroslav Raguž orcid id orcid.org/0000-0003-1567-8503 ; Dubrava University Hospital, Zagreb, Croatia
Šime Manola orcid id orcid.org/0000-0001-6444-2674 ; Dubrava University Hospital, Zagreb, Croatia


Puni tekst: engleski pdf 148 Kb

str. 478-478

preuzimanja: 106

citiraj

Preuzmi JATS datoteku


Sažetak

Ključne riječi

percutaneous coronary intervention; stent; drug coated balloon; coronary bioadaptor; bioresorbable scaffold

Hrčak ID:

328180

URI

https://hrcak.srce.hr/328180

Datum izdavanja:

13.12.2024.

Posjeta: 341 *



Introduction: Treatment of epicardial coronary artery stenosis in chronic and acute coronary syndromes has been constantly changing and developing. Currently, the concepts of „leaving nothing behind“ and doing lumen enlargement without permanent scaffolding irrespective of vessel diameter seem feasible, but the contemporary data are conflicting. (1) We present single center experience in percutaneous coronary intervention (PCI) techniques in acute and chronic coronary syndromes in regard to lumen enlargement and scaffolding.

Patients and Methods: We analyzed PCI techniques regarding techniques of lumen enlargement and scaffolding in 1577 patients treated between September 2022 and September 2024 and followed-up in a single center PCI registry.

Results: There were 843 (53%) patients who received PCI in acute coronary syndromes (ACS), and 734 (47%) patients with PCI in chronic coronary syndromes (CCS). Among ACS patients, 731 (87%) patients received drug eluting stents (DES), 104 (12%) patients were treated with drug coated balloon (DCB) dilatation only, whereas 8 patients (1%) received coronary bioadaptors. There were no differences in cardiovascular mortality or reinfarction within 30 days among different PCI strategies. There were more bleeding events during follow-up (5.6% vs 1.8%) among patients treated with DES in comparison to DCB. Among CCS patients, 468 (64%) patients received DES, 263 (35.5%) patients were treated with DCB dilatation only, whereas 3 (0.5%) patients received coronary bioadaptors, and only 1 patient received bioresorbable vascular scaffolds (BRS). There were no differences in cardiovascular mortality or target lesion failure within 30 days among PCI strategies. Posterolateral part of coronary circulation, bifurcations, late stent failures and distal segment involvement were predictors of DCB only use in both ACS and CCS.

Conclusion: DCB only PCI is significantly more represented among patients with CCS in comparison to ACS. In CCS, every third patient received a DCB only intervention. DCB only PCI had comparable short-term results and similar predictors of use in both ACS and CCS. Further studies on routine use of modern stentless PCI principles in both ACS and CCS are needed to evaluate its value as standard PCI techniques.

LITERATURE

1 

Gao C, He X, Ouyang F, Zhang Z, Shen G, Wu M, et al. REC-CAGEFREE I Investigators. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial. Lancet. 2024 September 14;404(10457):1040–50. https://doi.org/10.1016/S0140-6736(24)01594-0 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/39236727


This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.